• Strategic partnership with Hoshi International that holds European property, offering Flora with a transparent anticipated pathway to European distribution and the introduction of Flora’s merchandise, formulations, and types
  • Alignment between two sturdy administration groups. Hoshi’s administration crew has intensive entrepreneurial and management expertise in the worldwide hashish market
  • Processing foothold in the European Union for choose Flora applied sciences, such because the patented hemp cigarette manufacturing line that’s anticipated be acquired by way of the proposed Koch and Gsell acquisition
  • Leveraging Hoshi’s varied distribution agreements all through the European Union, together with the United Kingdom, Germany, and Poland, with extra distribution agreements being actively pursued and negotiated

MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), an all-outdoor cultivator and producer of world hashish merchandise and types, immediately introduced it has closed the previously announced2M (two-million Euros) funding in Hoshi International Inc. (“Hoshi”) whereas additionally growing its fully-diluted possession in Hoshi by way of a securities swap.

Further, Flora Growth and Hoshi have agreed to strengthen the phrases underwhich Flora Growth is investing in Hoshi pursuant to a binding memorandum of settlement, together with the next phrases:

  • Flora is entitled to appoint one Director to Hoshi’s Board of Directors, particularly Luis Merchan, Flora Growth’s President and CEO
  • Flora shall be Hoshi’s most well-liked provider of genetic materials and completed hashish by-product merchandise at its cultivation and processing facility in Portugal, topic to the events getting into right into a definitive settlement by October 1, 2021
  • Flora will maintain a proper of first refusal to produce any hashish oil or by-product merchandise acquired by Hoshi or any of its associates at its processing facility in Malta, topic to the events getting into right into a definitive settlement by October 1, 2021
  • Hoshi will use commercially cheap efforts to grant Flora entry to its European Union Good Manufacturing Practices (“EU-GMP”) auditors for the needs of helping Flora to acquire EU-GMP certification at its Cosechemos cultivation and extraction facility in Colombia

“The Hoshi team has developed a strong presence in Europe, and our high-quality, low-cost, medical-grade cannabis products and well-known global brands give both our companies a competitive advantage in one of the fastest growing cannabis markets in the world. We are excited to increase our alignment with the Hoshi management team and believe the partnership will be much greater in scope than only using their Portugal and Malta facilities as a European importation gateway for our Colombian cannabis flower and derivatives,” stated Luis Merchan, President and CEO of Flora. “Regulatory barriers and the technical requirements necessary to successfully navigate the European cannabis market should not be underestimated. We feel extremely pleased with the experience and expertise that the Hoshi team brings in order for us to quickly get our products to market. With the recent rule changes in Colombia allowing the export of THC and CBD flower, we are looking forward to bringing our premium Colombian flower and derivative products to established markets where there is already significant demand, growth, and the opportunity to generate recurring high-margin sales.”

2020 was a major yr for medical hashish in Europe in phrases of affected person entry and regulatory and industrial progress. According to the Federal Institute for Drugs and Medical Devices, German imports of licensed flower for medical functions in 2020 reached 9,231 kg. Although suppliers didn’t report the wholesale worth of those shipments, New Frontier Data estimated (from combination governmental figures) the value to be between €Four and €7 per gram. From January to September 2020, the worth of medical hashish transactions in Germany added as much as €111 million, with flower gross sales particularly comprising €54 million or appx. 48.6% of the market. Prohibition Partners notes that Germany leads the European hashish market in phrases of progress with over one million German sufferers estimated to have entry to medical hashish by 2024, and predicts the German medical hashish market alone to be price €7.7 billion by 2028. The agency additionally estimates the European hashish market to be price €403.Four million by the tip of 2021, rising at a compound annual progress price (CAGR) of 67.4% from 2021 to succeed in €3.2 billion by 2025.

“We are excited to begin working alongside the Flora team and sharing our understanding of the European market while working together to bring to market finished product formats from Flora’s brand portfolio that are suitable for European medical consumers,” stated John Aird, CEO of Hoshi. “Not only has Flora made an investment into Hoshi, but through our securities swap, the Hoshi management team also has a vested interest in the success of Flora Growth and our long-term working relationship.”

Flora will obtain 2,000,000 warrants from Hoshi administration to amass 2,000,000 widespread shares of Hoshi in alternate for 225,000 Flora widespread shares. This alternate will strengthen the long-term strategic alignment between Hoshi administration and Flora Growth in addition to growing Flora’s stake in Hoshi. As a part of the securities swap, Hoshi administration shall be topic to a share lock-up. The lock-up interval would be the lesser of 9 months or a the itemizing of Hoshi’s shares on a inventory alternate.

About Hoshi International Inc.

Hoshi is a European centered, totally built-in medical hashish firm led by a crew of famend hashish entrepreneurs. Hoshi is concentrated on growing and operationalizing property throughout the worldwide hashish trade with an emphasis on cultivating, manufacturing, and distributing hashish merchandise all through the EU. Hoshi is uniquely positioned to develop into a number one supplier of hashish and by-product merchandise for the rising European market.

About Flora Growth Corp.

Flora is a hashish firm that leverages pure, cost-effective cultivation practices to produce hashish derivatives to its numerous enterprise divisions of cosmetics, hemp textiles, and meals and beverage. As the operator of one of many largest outside cultivation services, Flora strives to market a higher-quality premium product at beneath market costs. By prioritizing pure components and value-chain sustainability throughout its portfolio, Flora creates premium merchandise that assist shoppers restore and thrive. Visit www.floragrowth.ca or comply with @floragrowthcorp on social for extra info.

Cautionary Statement Concerning Forward-Looking Statements

This doc accommodates forward-looking statements. In addition, now and again, we or our representatives might make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future occasions, which we derive from the data at the moment out there to us. Such forward-looking statements relate to future occasions or our future efficiency, together with: the influence of Flora’s funding in Hoshi; the Company’s means to enter into industrial agreements with Hoshi and the influence thereof; Hoshi’s efficiency and projections together with acquiring a public itemizing; our monetary efficiency and projections; our progress in income and earnings; and our enterprise prospects and alternatives. You can establish forward-looking statements by these that aren’t historic in nature, significantly those who use terminology resembling “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the unfavourable of those or comparable phrases. In evaluating these forward-looking statements, you must take into account varied components, together with: our means to alter the route of the Company; our means to maintain tempo with new know-how and altering market wants; and the aggressive atmosphere of our enterprise. These and different components might trigger our precise outcomes to vary materially from any forward-looking assertion. Forward-looking statements are solely predictions. The forward-looking occasions mentioned in this doc and different statements made now and again by us or our representatives might not happen, and precise occasions and outcomes might differ materially and are topic to dangers, uncertainties and assumptions about us. We undertake no obligation to publicly replace or revise any forward-looking assertion, whether or not on account of uncertainties and assumptions, or the forward-looking occasions mentioned in this doc and different statements made now and again by us or our representatives not occurring, besides as could also be required by relevant legislation.


Investor Relations:
Evan Veryard


Public Relations:
Cassandra Dowell

+1 (858) 264-6600


This post was initially printed on this site

Source link